Notably, combination of AXL inhibitor SGI-7079 with EGFR TKI erlotinib increased the sensitivity of mesenchymal-like tumor cells to erlotinib in a mouse xenograft NSCLC model [25]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.